Thrombolytic Therapy in Acute Myocardial Infarction
- 31 March 1990
- Vol. 97 (4) , 136S-145S
- https://doi.org/10.1378/chest.97.4_supplement.136s
Abstract
No abstract availableKeywords
This publication has 40 references indexed in Scilit:
- Myocardial reperfusion, limitation of infarct size, reduction of left ventricular dysfunction, and improved survival. Should the paradigm be expanded?Circulation, 1989
- Lessons from the European Cooperative recombinant tissue-type plasminogen activator (rt-PA) versus placebo trialJournal of the American College of Cardiology, 1988
- Tissue Plasminogen ActivatorNew England Journal of Medicine, 1988
- The German multicenter trial of anisoylated plasminogen streptokinase activator complex versus heparin for acute myocardial infarctionThe American Journal of Cardiology, 1988
- TRIAL OF TISSUE PLASMINOGEN ACTIVATOR FOR MORTALITY REDUCTION IN ACUTE MYOCARDIAL INFARCTIONThe Lancet, 1988
- LONG-TERM EFFECTS OF INTRAVENOUS THROMBOLYSIS IN ACUTE MYOCARDIAL INFARCTION: FINAL REPORT OF THE GISSI STUDYThe Lancet, 1987
- Pharmacology of thrombolytic drugsJournal of the American College of Cardiology, 1986
- The Thrombolysis in Myocardial Infarction (TIMI) TrialNew England Journal of Medicine, 1985
- Thrombolytic TherapyNew England Journal of Medicine, 1982
- Prevalence of Total Coronary Occlusion during the Early Hours of Transmural Myocardial InfarctionNew England Journal of Medicine, 1980